RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -11.22% | -64.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.22% | -64.08% | |||
| Cost of Revenue | -18.20% | -40.79% | |||
| Gross Profit | -7.38% | -70.58% | |||
| SG&A Expenses | -12.09% | -43.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 163.64% | -97.60% | |||
| Total Operating Expenses | -12.28% | -44.62% | |||
| Operating Income | 12.51% | 36.86% | |||
| Income Before Tax | 63.81% | 89.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 63.81% | 89.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.81% | 89.16% | |||
| EBIT | 12.51% | 36.86% | |||
| EBITDA | 11.77% | 39.87% | |||
| EPS Basic | 63.83% | 89.12% | |||
| Normalized Basic EPS | 71.05% | 61.22% | |||
| EPS Diluted | 63.83% | 89.12% | |||
| Normalized Diluted EPS | 71.05% | 61.22% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||